National Bank of Canada
DNLI icon

National Bank of Canada’s Denali Therapeutics DNLI Stock Holding History

National Bank of Canada’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$726 – 2943
2025
Q3 		$726 Sell
50
-122
-71% -$1.75K ﹤0.01% 2668
2025
Q2 		$2.4K Buy
172
+102
+146% +$1.44K ﹤0.01% 2599
2025
Q1 		$952 Buy
70
+63
+900% +$1.21K ﹤0.01% 2582
2024
Q4 		$143 Sell
7
-27
-79% -$691 ﹤0.01% 2775
2024
Q3 		$990 Buy
+34
New +$843 ﹤0.01% 2424

Other funds holding DNLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

National Bank of Canada's DNLI Position: Q4 2025 in Review

National Bank of Canada sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 50 shares — an estimated $726 sold.

National Bank of Canada first reported a position in DNLI in Q3 2024 and held it in 5 quarters. The position peaked at $2.4K in Q2 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

  • National Bank of Canada reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 50 Denali Therapeutics shares in Q4 2025, an estimated $726.
  • National Bank of Canada first reported a position in Denali Therapeutics in Q3 2024 and held it in 5 quarters.
  • National Bank of Canada's Denali Therapeutics position peaked at $2.4K in Q2 2025.
  • 250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.